Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry
Authors:
- Moisés MercadoMMMoisés Mercado
- Coralys AbreuCACoralys Abreu
- Alma Vergara-LópezAVAlma Vergara-López
- Baldomero González-VirlaBGBaldomero González-Virla
- Ana-Laura Espinosa-De-Los-MonterosAEAna-Laura Espinosa-De-Los-Monteros
- Ernesto Sosa-ErozaESErnesto Sosa-Eroza
- Diego Cadena-ObandoDCDiego Cadena-Obando
- Daniel Cuevas-RamosDCDaniel Cuevas-Ramos
- Lesly A Portocarrero-OrtizLPLesly A Portocarrero-Ortiz
- Sara-Patricia Pérez-ReyesSPSara-Patricia Pérez-Reyes
- Raúl Ibarra-SalceRIRaúl Ibarra-Salce
Open Access
- 18 September 2020
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (12) , e4567-e4576
Abstract
Context: Acromegaly registries constitute a valuable source of therapeutic outcome information in real-life. Objective: The objective of this work is to analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Design and Methods: Data were extracted from the MAR informatic platform. Surgical remission was defined by a postoperative postglucose (GH) of less than 1 ng/mL and an insulin-like growth factor 1 (IGF-1) of less than 1.2 × upper limit of normal (ULN). Pharmacological remission was defined by a basal GH of less than 1 ng/mL and an IGF-1 of less than 1.2 × ULN. Results: A total of 650 surgical outcomes were analyzed (94.6% transsphenoidal). Surgical remission was achieved in 40.15%, whereas 44.15% remained biochemically active. Persistently active disease after surgery was significantly associated with harboring an invasive macroadenoma, a basal GH of greater than 10 ng/mL, and/or an IGF-1 of greater than 2 × ULN at diagnosis on bivariate and multivariate analysis. The outcome of monotherapy with first-generation somatostatin analogs (SSAs) was evaluated in 267 patients (adjunctive in 65%), of whom 28.4% achieved remission. Persistently active disease was significantly associated with harboring an invasive macroadenoma as well as with pretreatment basal GH and IGF-1 levels of greater than 10 ng/mL and greater than 2 × ULN, respectively, on bivariate and multivariate analysis. Combined therapy with SSA and cabergoline was analyzed in 100 patients, of whom 19% achieved remission and 44% remained active; in this subset of patients, only a pretreatment IGF-1 of greater than 2 × ULN was significantly associated with persistent disease activity. Conclusion: Surgical and pharmacological outcomes in acromegaly are highly dependent on tumor size/invasiveness as well as on the degree of hypersomatotropinemia.Keywords
Funding Information
- Novartis Oncology
- Ipsen Pharmaceuticals
This publication has 26 references indexed in Scilit:
- Acromegaly: Role of Surgery in the Therapeutic ArmamentariumInternational Journal of Endocrinology, 2012
- Place of Cabergoline in Acromegaly: A Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2011
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release OctreotideNeuroendocrinology, 2009
- Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly RegisterEuropean Journal of Endocrinology, 2008
- AcroBel – the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjectsEuropean Journal of Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease statusClinical Endocrinology, 2006
- Re‐evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patientsClinical Endocrinology, 2005
- Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin statusClinical Endocrinology, 2004